Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Drug: Rivaroxaban

Preclinical

CCombined military hospital lahore

Drug: Rivaroxaban is one of 2 therapeutic programs targeting Pulmonary Embolism Acute. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pulmonary Embolism AcuteCompleted

Pulmonary Embolism AcutePreclinical

Completed

Competition

Competitive Landscape

1 competitor in Pulmonary Embolism Acute

#DrugCompanyPhaseTrials

Anticoagulation

HHospital Álvaro Cunqueiro

Drug: Rivaroxaban

CCombined military hospital lahore

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Embolism Acute1 trial

Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism: A Single-Center Randomized Controlled Trial in Pakistan

Completed·CCombined military hospital lahore·Preclinical·NCT07774273·540 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Rivaroxaban. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug: Rivaroxaban. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Combined military hospital lahore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCombined military hospital lahore

Related News